SAMA confirms extension of payment deferral program until Q1 2021-end

SAMA confirms extension of payment deferral program until Q1 2021-end
The move comes as part of SAMA’s efforts to enable the financial sector to play its key role in supporting the private sector. (Shutterstock)
Short Url
Updated 30 November 2020

SAMA confirms extension of payment deferral program until Q1 2021-end

SAMA confirms extension of payment deferral program until Q1 2021-end
  • Around 87,000 beneficiaries have taken part in the program since its launch on March 14, 2020

The Saudi Central Bank (SAMA) announced extending the deferred payment program to support the private sector until Q1 2021-end.

The move comes as part of SAMA’s efforts to enable the financial sector to play its key role in supporting the private sector, particularly the micro, small and medium-sized enterprises, the central bank said in a statement.

The decision also enables SAMA to maintain financial sector’s stability and support economic growth, in line with the Kingdom’s efforts to mitigate the COVID-19 pandemic fallout on various economic sectors.

The number of beneficiaries from the program, since its launch on March 14, 2020, exceeded 87,000 with SAR 77.3 billion ($20.6 billion) deferred payments, the statement added.

On Sept. 1, 2020, SAMA decided to extend the payment deferral program for 3 more months until December 14, Argaam earlier reported.

Powered by Argaam


Dr. Iman Al-Mansour, assistant professor at the Institute for Research and Medical Consultations in Dammam

Dr. Iman Al-Mansour, assistant professor at the Institute for Research and Medical Consultations in Dammam
Updated 59 min 49 sec ago

Dr. Iman Al-Mansour, assistant professor at the Institute for Research and Medical Consultations in Dammam

Dr. Iman Al-Mansour, assistant professor at the Institute for Research and Medical Consultations in Dammam

Dr. Iman Al-Mansour is an assistant professor of epidemiology at the Institute for Research and Medical Consultations (IRMC), affiliated with Imam Abdulrahman Bin Faisal University (IAU), in Dammam.

Al-Mansour led many research projects from conception to execution at the department of epidemic diseases research at IAU and supervised graduate students and junior scientists.

She acted as the principal investigator on a number of key research projects related to the development of nucleic acid-based vaccines, the establishment of several virus bioinformatics databases and analysis resources, and virus immune monitoring studies.

Al-Mansour believes that investment in vaccine research is an important step to combat epidemics and pandemics caused by new viruses. This is followed by the localization of the manufacturing of vaccines and biological medicines.

She served as a Ph.D. researcher at the nucleic acid vaccine (NAV) lab at the University of Massachusetts, US, where she conducted rigorous research in the design, generation, and testing of DNA vaccines expressing HA’s of influenza (H1N1) strains.

Al-Mansour’s research is focused on cutting-edge technology to develop prophylactic vaccines against emerging and re-emerging viruses.

She earned a Ph.D. in biomedical engineering and biotechnology from the University of Massachusetts, US, and a master’s degree in clinical laboratory sciences from the University of Rhode Island, US.

Al-Mansour received her bachelor’s in medical laboratory technology from IAU.

She is also an academic member at the European Virus Bioinformatics Center (EVBC), Germany, and a member at the International Society for Global health (ISoGH), in the UK.